Autolus Therapeutics strengthens its Board with the appointment of Dr. Robert Iannone as a Non-Executive Director LONDON, June 20, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces...